Edgewise Therapeutics Inc (EWTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Edgewise Therapeutics Inc (EWTX) has a cash flow conversion efficiency ratio of -0.086x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.54 Million) by net assets ($493.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Edgewise Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Edgewise Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Edgewise Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Edgewise Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Edgewise Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
VEON Ltd
NASDAQ:VEON
|
0.196x |
|
Holmen AB (publ)
ST:HOLM-B
|
0.023x |
|
Fosun International Limited
F:FNI
|
0.045x |
|
Delhivery Limited
NSE:DELHIVERY
|
0.022x |
|
WSFS Financial Corporation
NASDAQ:WSFS
|
0.045x |
|
GRG Banking Equipment Co Ltd
SHE:002152
|
0.028x |
|
FIT Hon Teng Limited
F:0FJ
|
0.040x |
|
Heilongjiang Agriculture Co Ltd
SHG:600598
|
-0.195x |
Annual Cash Flow Conversion Efficiency for Edgewise Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Edgewise Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see EWTX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $522.26 Million | $-143.82 Million | -0.275x | -15.99% |
| 2024-12-31 | $459.22 Million | $-109.03 Million | -0.237x | +17.67% |
| 2023-12-31 | $318.83 Million | $-91.95 Million | -0.288x | -89.97% |
| 2022-12-31 | $346.72 Million | $-52.63 Million | -0.152x | -24.31% |
| 2021-12-31 | $274.38 Million | $-33.51 Million | -0.122x | -127.89% |
| 2020-12-31 | $-33.42 Million | $-14.63 Million | 0.438x | -19.53% |
| 2019-12-31 | $-16.85 Million | $-9.17 Million | 0.544x | -- |
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more